The company has been granted 1 product patent from Australia and 1 product patent from Singapore corresponding to the new chemical entities.
Share price of Suven Life Sciences added 3 percent intraday Wednesday after company secured product patents in Australia and Singapore.
The company has been granted 1 product patent from Australia and 1 product patent from Singapore corresponding to the new chemical entities for the treatment of disorders associated with Neurodegenerative diseases.
These patents are valid through 2036.
The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc, company said in release.
Venkat Jasti, CEO of Suven said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
At 10:56 hrs Suven Life Sciences was quoting at Rs 223.60, up Rs 4.55, or 2.08 percent on the BSE.
For more market news, click here
